RECURrence of Atrial Fibrillation after cardioversion of patients randomized to open-label treatment with dapagliflozin or usual care (RECUR-AF)

Status

Recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513719-28-00

Enrollment

1600

Registered

2024-08-14

Start date

2025-06-04

Completion date

Unknown

Last updated

2024-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation

Brief summary

Time to recurrence of AF within 30 days after cardioversion.

Detailed description

Proportion of patients in sinus rhythm (SR) 30 days after cardioversion., Proportion of patients without any AF recurrence at 30 days, Time to spontaneous return to SR before electrical cardioversion., Spontaneous return to SR before cardioversion., Success of cardioversion (discharged with SR)., Total number of days with AF recordings during 30 days following cardioversion., Absence of clinical AF recurrence (12- lead ECG-verified) during follow-up after EC or after spontaneous return to SR (before EC).

Interventions

DRUGDAPAGLIFLOZIN

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Time to recurrence of AF within 30 days after cardioversion.	—

Secondary

Measure	Time frame
Proportion of patients in sinus rhythm (SR) 30 days after cardioversion., Proportion of patients without any AF recurrence at 30 days, Time to spontaneous return to SR before electrical cardioversion., Spontaneous return to SR before cardioversion., Success of cardioversion (discharged with SR)., Total number of days with AF recordings during 30 days following cardioversion., Absence of clinical AF recurrence (12- lead ECG-verified) during follow-up after EC or after spontaneous return to SR (before EC).	—

Measure

Time frame

—

Countries

Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026